The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Medvedev S.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Bychkova N.M.

Herzen Moscow Research Oncology Institute

Khmelevsky E.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Efficiency of hypofractionated radiotherapy for bone metastases in a female patient with advanced skin melanoma

Authors:

Medvedev S.V., Bychkova N.M., Khmelevsky E.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(4): 62‑65

DOI: 10.17116/onkolog20221104162

Read: 1131 times

Contact the author
Table of contents

EFFICIENCY OF HYPOFRACTIONATED RADIOTHERAPY FOR BONE METASTASES IN A FEMALE PATIENT WITH ADVANCED SKIN MELANOMA
EFFICIENCY OF HYPOFRACTIONATED RADIOTHERAPY FOR BONE METASTASES IN A FEMALE PATIENT WITH ADVANCED SKIN MELANOMA

To cite this article:

Medvedev SV, Bychkova NM, Khmelevsky EV. Efficiency of hypofractionated radiotherapy for bone metastases in a female patient with advanced skin melanoma. P.A. Herzen Journal of Oncology. 2022;11(4):62‑65. (In Russ.)
https://doi.org/10.17116/onkolog20221104162

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Proton therapy of skull base chordoma. P.A. Herzen Journal of Onco­logy. 2025;(5):64-67
Fluorescent in situ-hybridization (FISH) in onco­logy. P.A. Herzen Journal of Onco­logy. 2025;(6):88-93
Lean mana­gement example at the radiotherapy depa­rtment. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):67-73
Prevention and treatment of dermal toxi­city in children receiving anti-tumor radiation. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):470-480
Function-sparing surgery for subu­ngual mela­noma in situ. Piro­gov Russian Journal of Surgery. 2025;(11):141-144
Dysplastic nevi: difficulties in diagnosis. Russian Journal of Archive of Pathology. 2025;(6):12-19
Hypo­fractionated irra­diation for intracranial meni­ngiomas. Burdenko's Journal of Neurosurgery. 2025;(6-2):21-28
Overall survival prediction scale for patients with grade 4 brain astrocytoma. Burdenko's Journal of Neurosurgery. 2026;(1):65-72
Abstract:

Metastatic bone lesion in skin melanoma is a frequent localization of tumor dissemination and occurs in 45% of cases, leading to significantly reduced quality of life due to severe pain. On account of the historical perception of skin melanoma as a highly radioresistant tumor, some oncologists even now oppose radiotherapy for this pathology. However, the reputation of melanoma as a tumor resistant to radiotherapy has not been confirmed by a hypofractionated radiotherapy dose scheme.

Keywords:

bone metastases
melanoma
radiotherapy
beam therapy

Authors:

Medvedev S.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Bychkova N.M.

Herzen Moscow Research Oncology Institute

Khmelevsky E.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Received:

21.04.2022

Accepted:

27.04.2022

Close metadata

References:

  1. Kaprin AD, Starinskii VV, Petrova GV. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2015. M.: MNIOI im. P.A. Gertsena; 2016.
  2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-76.  https://doi.org/10.1053/ctrv.2000.0210
  3. Huang R, Zeng Z, Li G, Song D, Yan P, Yin H, Hu P, Zhu X, Chang R, Zhang X, Zhang J, Meng T, Huang Z. The construction and comprehensive analysis of ceRNA networks and tumor-infiltrating immune cells in bone metastatic melanoma. Front Genet. 2019;10:828.  https://doi.org/10.3389/fgene.2019.00828
  4. Fidler I, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst. 1990;82(3):166-168.  https://doi.org/10.1093/jnci/82.3.166
  5. Khan N, Khan MK, Almasan A, Singh AD, Macklis R. The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys. 2011;80(3):645-654.  https://doi.org/10.1016/j.ijrobp.2010.12.071
  6. Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys. 1986;12(6):867-872.  https://doi.org/10.1016/0360-3016(86)90378-0
  7. Konefal JB, Emami B, Pilepich MV. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology. 1987;164(3):607-610.  https://doi.org/10.1148/radiology.164.3.3112864
  8. Bentzen SM, Overgaard J, Thames HD, Overgaard M, Vejby Hansen P, von der Maase H, Meder J. Clinical radiobiology of malignant melanoma. Radiother Oncol. 1989;16(3):169-182.  https://doi.org/10.1016/0167-8140(89)90017-0
  9. Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol. 1986;5(3):183-192.  https://doi.org/10.1016/s0167-8140(86)80048-2
  10. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, Janjan N, Lipsett J. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991;20(3):429-432.  https://doi.org/10.1016/0360-3016(91)90053-7
  11. Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys. 1985;11(10):1837-1839. https://doi.org/10.1016/0360-3016(85)90042-2
  12. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.  https://doi.org/10.1038/nrc3239
  13. Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8(3):410-416.  https://doi.org/10.7150/jca.17144
  14. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.  https://doi.org/10.1056/NEJMoa1412082
  15. https://doi.org/10.17116/onkolog20165612-20  https://doi.org/10.17116/onkolog20165612-20
  16. https://doi.org/10.17116/onkolog2020903161  https://doi.org/10.17116/onkolog2020903161
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.